Cargando…

Potentiating the Cross-Reactive IFN-γ T Cell and Polyfunctional T Cell Responses by Heterologous GX-19N DNA Booster in Mice Primed with Either a COVID-19 mRNA Vaccine or Inactivated Vaccine

Waning vaccine-induced immunity, coupled with the emergence of SARS-CoV-2 variants, has inspired the widespread implementation of COVID-19 booster vaccinations. Here, we evaluated the potential of the GX-19N DNA vaccine as a heterologous booster to enhance the protective immune response to SARS-CoV-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Yong Bok, Ko, Ara, Shin, Duckhyang, Kim, Junyoung, Suh, You Suk, Na, Juyoung, Ryu, Ji In, Lee, Suyeon, Oh, Min Ji, Sung, Young Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253410/ https://www.ncbi.nlm.nih.gov/pubmed/37298704 http://dx.doi.org/10.3390/ijms24119753

Ejemplares similares

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
por: Goh, Yun Shan, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Publicado: (2023)

Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against Trypanosoma cruzi
por: Sanchez Alberti, Andrés, et al.
Publicado: (2020)

Homologous and Heterologous Covid-19 Booster Vaccinations
por: Atmar, Robert L., et al.
Publicado: (2022)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs
por: Saltoğlu, Neşe, et al.
Publicado: (2022)

Effectiveness of Heterologous COVID-19 Vaccine Booster in Korean Elderly Population, 2022
por: Park, Seon Kyeong, et al.
Publicado: (2023)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection
por: Hyun, Hakjun, et al.
Publicado: (2023)

Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study
por: Pugliese, Maria Elena, et al.
Publicado: (2022)

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
por: Ranzani, Otavio T., et al.
Publicado: (2022)

Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?
por: Gelanew, Tesfaye, et al.
Publicado: (2023)

Humoral response to heterologous prime‐booster vaccination in heart transplant recipients aged 18–70 years primed with a viral vector SARS‐CoV‐2 vaccine
por: Tanner, Richard, et al.
Publicado: (2022)

Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals
por: Mallah, Saad I., et al.
Publicado: (2023)

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
por: Das, Rituparna, et al.
Publicado: (2023)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine
por: Rzymski, Piotr, et al.
Publicado: (2022)

Safety and Immunogenicity of Inactivated Bacillus subtilis Spores as a Heterologous Antibody Booster for COVID-19 Vaccines
por: Sung, Johnny Chun-Chau, et al.
Publicado: (2022)

Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report
por: Atmar, Robert L., et al.
Publicado: (2021)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
por: He, Qian, et al.
Publicado: (2021)

Adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Polyfunctional CD4(+) T Cells As Targets for Tuberculosis Vaccination
por: Lewinsohn, Deborah A., et al.
Publicado: (2017)

The acceptance to heterologous booster vaccination of COVID-19 vaccine among HCWs and targeted population: A cross-sectional study in central China
por: Qin, Wei, et al.
Publicado: (2022)

Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations
por: Wei, Yunhua, et al.
Publicado: (2022)

REACTOGENICITY OF HETEROLOGOUS MRNA-BASED COVID-19 VACCINE BOOSTER IN YOUNG ADULTS IN INDONESIA- A SHORT COMMUNICATION.
por: Neneng, SURYADINATA, et al.
Publicado: (2023)

Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide
Publicado: (1991)

Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans
por: Mayr, Florian B., et al.
Publicado: (2022)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy
por: Raposo, Francisco, et al.
Publicado: (2021)

The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2
por: Ho, Tzu-Chuan, et al.
Publicado: (2021)

Adopting an heterologous prime-boost strategy in COVID-19 vaccination: the need for locally generated evidence in Africa
por: Oboh, Mary Aigbiremo, et al.
Publicado: (2022)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID-19 prime-boost vaccinations
por: Cheng, Aristine, et al.
Publicado: (2023)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Cheng, Aristine, et al.
Publicado: (2023)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study
por: Sripongpun, Pimsiri, et al.
Publicado: (2023)

Evaluation of Antibody Response and Adverse Effects following Heterologous COVID-19 Vaccine Booster with mRNA Vaccine among Healthcare Workers in Indonesia
por: Soegiarto, Gatot, et al.
Publicado: (2023)

The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines
por: Al-Kubati, Anwar A. G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8pc1v539p3ls6t4n64ten9rrk4